ACADIA PHARMACEUTICALS INC. Increase (Decrease) in Prepaid Expense
ACADIA PHARMACEUTICALS INC. (ACAD) reported Increase (Decrease) in Prepaid Expense of $5.07 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-05-07
- ACADIA PHARMACEUTICALS INC. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was $5.07M.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was $8.12M, a 47.82% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in prepaid expense for the quarter ending 2025-06-30 was $44.00K, a 98.66% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. increase (decrease) in prepaid expense for the quarter ending 2025-03-31 was -$2.98M, a 181.14% decline year-over-year.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month |
|---|---|---|---|
| 2026-03-31 | $5.07M 10-Q · filed 2026-05-07 | ||
| 2025-09-30 | $8.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.16M derived: sum of 2 quarters · filed 2025-11-06 | $5.19M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $44.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$2.93M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | -$2.98M 10-Q · filed 2026-05-07 | ||
| 2024-09-30 | $5.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.79M derived: sum of 2 quarters · filed 2025-11-06 | $12.46M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $3.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $6.96M 10-Q · filed 2025-08-07 | |
| 2024-03-31 | $3.67M 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | $14.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $14.32M derived: sum of 2 quarters · filed 2024-11-07 | $16.55M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $263.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $2.50M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | $2.23M 10-Q · filed 2024-05-09 | ||
| 2022-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | -$2.76M derived: sum of 2 quarters · filed 2023-11-03 | -$899.00K 10-Q · filed 2023-11-03 |
| 2022-06-30 | -$4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.94M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $1.86M 10-Q · filed 2023-05-08 | ||
| 2021-09-30 | -$1.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.89M derived: sum of 2 quarters · filed 2022-11-03 | -$1.07M 10-Q · filed 2022-11-03 |
| 2021-06-30 | -$2.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $512.00K 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $2.82M 10-Q · filed 2022-05-05 | ||
| 2020-09-30 | $5.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $7.88M derived: sum of 2 quarters · filed 2021-11-09 | $11.40M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $2.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $6.24M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $3.52M 10-Q · filed 2021-05-06 | ||
| 2019-09-30 | $2.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$2.37M derived: sum of 2 quarters · filed 2020-11-04 | $641.00K 10-Q · filed 2020-11-04 |
| 2019-06-30 | -$5.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$2.22M 10-Q · filed 2020-08-06 | |
| 2019-03-31 | $3.02M 10-Q · filed 2020-05-08 | ||
| 2018-09-30 | $2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31 | $1.93M derived: sum of 2 quarters · filed 2019-10-31 | $6.49M 10-Q · filed 2019-10-31 |
| 2018-06-30 | -$198.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $4.37M 10-Q · filed 2019-08-01 | |
| 2018-03-31 | $4.56M 10-Q · filed 2019-05-02 | ||
| 2017-09-30 | $6.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $7.68M derived: sum of 2 quarters · filed 2018-11-06 | $7.01M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $498.00K 10-Q · filed 2018-08-08 | |
| 2017-03-31 | -$674.00K 10-Q · filed 2018-05-04 | ||
| 2016-03-31 | $2.11M 10-Q · filed 2017-05-09 | ||
| 2014-03-31 | $73.00K 10-Q · filed 2014-05-06 | ||
| 2013-03-31 | $761.00K 10-Q · filed 2014-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |